Author:
Saul S M,Duprez D A,Zhong W,Grandits G A,Cohn J N
Publisher
Springer Science and Business Media LLC
Reference40 articles.
1. Cohn JN . Should the blood pressure or the blood vessel be the target of therapy? Expert Rev Cardiovasc Ther 2011; 9 (11): 1397–1401.
2. de Luca N, Mallion JM, O'Rourke MF, O’Brien E, Rahn KH, Trimarco B et al. Regression of left ventricular mass in hypertensive patients treated with perindopril/indapamide as a first-line combination: the REASON echocardiography study. Am J Hypertens 2004; 17 (8): 660–667.
3. Asmar RG, London GM, O’Rourke ME, Mallion JM, Romero R, Rahn KH et al. REASON Project Investigators (pREterax in regression of Arterial Stiffness in a contrOlled double-bliNd Study). Amelioration of arterial properties with a perindopril-indapamide very-low-dose combination. J Hypertens Suppl 2001; 19 (4): S15–S20.
4. Virdis A, Ghiadoni L, Qasem AA, Lorenzini G, Duranti E, Cartoni G et al. Effect of aliskiren treatment on endothelium-dependent vasodilation and aortic stiffness in essential hypertensive patients. Eur Heart J 2012; 33 (12): 1530–1538.
5. White WB, Duprez D, St Hillaire R, Krause S, Roniker B, Kuse-Hamilton J et al. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 2003; 41 (5): 1021–1026.
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献